Prognosis of Brain Metastases (BM) Patient Received Whole Brain Radiation Therapy (WBRT) alone or in combination with Surgery at Dharmais National Cancer Center, Indonesia.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2025-06-01 DOI:10.31557/APJCP.2025.26.6.2025

Rini Andriani, Umi Mangesti Tjiptoningsih, Octavia So Hanggrainy, Alfred Susilodinata, Siswanto Agus Wilopo

{"title":"Prognosis of Brain Metastases (BM) Patient Received Whole Brain Radiation Therapy (WBRT) alone or in combination with Surgery at Dharmais National Cancer Center, Indonesia.","authors":"Rini Andriani, Umi Mangesti Tjiptoningsih, Octavia So Hanggrainy, Alfred Susilodinata, Siswanto Agus Wilopo","doi":"10.31557/APJCP.2025.26.6.2025","DOIUrl":null,"url":null,"abstract":"Purpose: WBRT and surgery are commonly used to improve the overall survival of BM patients. The study aims to evaluate the overall survival of patients treated with WBRT in combination with surgery or alone.Methods: This study is a cohort retrospective of 148 BM patients from January 1st, 2021, to December 31st, 2022, and our follow-up on their overall survival up to July 1st, 2023. We collected data on treatments received either in combination with WBRT and surgery or alone. Information for age, sex, primary tumor types, and sites of metastases were collected. Median survival time, Kaplan-Meier curves, and its' log-rank statistics were presented, including the results of Cox regression analysis.Results: The overall median survival of this sample was 4.3 months. Patients receiving WBRT exhibit higher survival rates than non-WBRT (median survival rates are 6.9 vs 1.5 months) but not surgery (4.0 vs 4.4 months). The primary tumors (breast, lung, and others) have no difference in the median survival rates. The survival rate using Kaplan-Meier showed a significant difference between patients with WBRT vs non-WBRT (log-rank p=0.0) but not for surgery. A Cox regression shows hazard ratio (HR) for patients receiving WBRT=0.34 [95% CI: 0.19-0.62; P<0.001] and when it is adjusted for surgery and other variables it exhibits only a small change.Conclusion: BM patients who received WBRT had better survival than non-WBRT patients, which could reduce HR, but surgery was not statistically significant. All BM patients should receive WBRT regardless of surgery.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"2025-2034"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.6.2025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: WBRT and surgery are commonly used to improve the overall survival of BM patients. The study aims to evaluate the overall survival of patients treated with WBRT in combination with surgery or alone.

Methods: This study is a cohort retrospective of 148 BM patients from January 1st, 2021, to December 31st, 2022, and our follow-up on their overall survival up to July 1st, 2023. We collected data on treatments received either in combination with WBRT and surgery or alone. Information for age, sex, primary tumor types, and sites of metastases were collected. Median survival time, Kaplan-Meier curves, and its' log-rank statistics were presented, including the results of Cox regression analysis.

Results: The overall median survival of this sample was 4.3 months. Patients receiving WBRT exhibit higher survival rates than non-WBRT (median survival rates are 6.9 vs 1.5 months) but not surgery (4.0 vs 4.4 months). The primary tumors (breast, lung, and others) have no difference in the median survival rates. The survival rate using Kaplan-Meier showed a significant difference between patients with WBRT vs non-WBRT (log-rank p=0.0) but not for surgery. A Cox regression shows hazard ratio (HR) for patients receiving WBRT=0.34 [95% CI: 0.19-0.62; P<0.001] and when it is adjusted for surgery and other variables it exhibits only a small change.

Conclusion: BM patients who received WBRT had better survival than non-WBRT patients, which could reduce HR, but surgery was not statistically significant. All BM patients should receive WBRT regardless of surgery.

查看原文本刊更多论文

脑转移瘤（BM）患者在印度尼西亚Dharmais国家癌症中心单独或联合手术接受全脑放疗（WBRT）的预后。

目的：WBRT联合手术是提高BM患者总生存率的常用方法。该研究旨在评估WBRT联合手术或单独治疗的患者的总生存率。方法：本研究对从2021年1月1日至2022年12月31日的148例BM患者进行队列回顾性研究，并对其总生存期进行随访至2023年7月1日。我们收集了WBRT联合手术或单独治疗的数据。收集了年龄、性别、原发肿瘤类型和转移部位的信息。给出中位生存时间、Kaplan-Meier曲线及其log-rank统计量，包括Cox回归分析结果。结果：该样本的总中位生存期为4.3个月。接受WBRT的患者比未接受WBRT的患者表现出更高的生存率（中位生存率为6.9个月对1.5个月），但没有手术（4.0个月对4.4个月）。原发肿瘤（乳腺、肺和其他肿瘤）的中位生存率没有差异。Kaplan-Meier法显示，WBRT患者与非WBRT患者的生存率存在显著差异（log-rank p=0.0），但手术患者的生存率无显著差异。Cox回归分析显示，接受WBRT的患者的风险比(HR) =0.34 [95% CI: 0.19-0.62；结论：BM患者接受WBRT的生存率高于未接受WBRT的患者，可降低HR，但手术效果无统计学意义。所有BM患者均应接受WBRT，无论是否手术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.